New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 12, 2021 - the FDA announced the approval of PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft), for the treatment of adults with polycythemia vera.
Download PDF
Return to publications
